BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9524829)

  • 1. Posttransplantation lymphoproliferative disorder associated with OKT3 and decreased antiviral prophylaxis in pancreas transplant recipients.
    Keay S; Oldach D; Wiland A; Klassen D; Schweitzer E; Abruzzo LV; Kumar D; Bartlett S
    Clin Infect Dis; 1998 Mar; 26(3):596-600. PubMed ID: 9524829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy.
    Darenkov IA; Marcarelli MA; Basadonna GP; Friedman AL; Lorber KM; Howe JG; Crouch J; Bia MJ; Kliger AS; Lorber MI
    Transplantation; 1997 Sep; 64(6):848-52. PubMed ID: 9326409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation.
    Valenza M; Czer LS; Pan SH; Aleksic I; Freimark D; Harasty DA; Admon D; Barath P; Blanche C; Trento A
    J Heart Lung Transplant; 1995; 14(4):659-65. PubMed ID: 7578172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
    Davis CL; Harrison KL; McVicar JP; Forg PJ; Bronner MP; Marsh CL
    Clin Transplant; 1995 Feb; 9(1):53-9. PubMed ID: 7742583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current induction immunosuppression and post-heart transplant lymphoproliferative disorders.
    Peraira JR; Segovia J; Fuertes B; Fernández JA; Escudier JM; Salas C; Pulpón LA
    Transplant Proc; 2003 Aug; 35(5):2009-10. PubMed ID: 12962879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S; Zafar MN; Best J; Reddy HK
    J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OKT3 and ganciclovir treatments are possibly related to the presence of Epstein-Barr virus in serum after liver transplantation.
    Barkholt L; Linde A; Falk KI
    Transpl Int; 2005 Jul; 18(7):835-43. PubMed ID: 15948864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University.
    Gao SZ; Chaparro SV; Perlroth M; Montoya JG; Miller JL; DiMiceli S; Hastie T; Oyer PE; Schroeder J
    J Heart Lung Transplant; 2003 May; 22(5):505-14. PubMed ID: 12742411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posttransplantation lymphoproliferative disorder: changing manifestations of disease in a renal transplant population.
    Miller WT; Siegel SG; Montone KT
    Crit Rev Diagn Imaging; 1997 Dec; 38(6):569-85. PubMed ID: 9442979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute renal allograft rejection in patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder.
    Purighalla R; Shapiro R; Jordan ML; Scantlebury VP; Gritsch HA; Vivas C; Randhawa PS
    Clin Transplant; 1997 Dec; 11(6):574-6. PubMed ID: 9408687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
    Younes BS; McDiarmid SV; Martin MG; Vargas JH; Goss JA; Busuttil RW; Ament ME
    Transplantation; 2000 Jul; 70(1):94-9. PubMed ID: 10919581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of induction therapy, immunosuppressive regimen and anti-viral prophylaxis on development of lymphomas after heart transplantation: data from the Spanish Post-Heart Transplant Tumour Registry.
    Crespo-Leiro MG; Alonso-Pulpón L; Arizón JM; Almenar L; Delgado JF; Palomo J; Manito N; Rábago G; Lage E; Diaz B; Roig E; Pascual D; Blasco T; de la Fuente L; Campreciós M; Vázquez de Prada JA; Muñiz J
    J Heart Lung Transplant; 2007 Nov; 26(11):1105-9. PubMed ID: 18022075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients.
    Funch DP; Walker AM; Schneider G; Ziyadeh NJ; Pescovitz MD
    Am J Transplant; 2005 Dec; 5(12):2894-900. PubMed ID: 16303002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus preemptive therapy with ganciclovir in renal transplant patients treated with OKT3.
    Gómez E; de Oña M; Aguado S; Tejada F; Nuñez M; Portal C; Diaz-Corte C; Sanchez E; Ortega F; Alvarez-Grande J
    Nephron; 1996; 74(2):367-72. PubMed ID: 8893157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se?
    Birkeland SA; Hamilton-Dutoit S
    Transplantation; 2003 Sep; 76(6):984-8. PubMed ID: 14508366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Early diagnosis and comprehensive treatments of post-transplantation lymphoproliferative disorder after pediatric liver transplantation].
    Deng Z; Jiang L; Zhou T; Shen C; Chen Q; Xia Q
    Zhonghua Er Ke Za Zhi; 2014 Aug; 52(8):579-82. PubMed ID: 25224233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretransplantation assessment of the risk of lymphoproliferative disorder.
    Walker RC; Marshall WF; Strickler JG; Wiesner RH; Velosa JA; Habermann TM; McGregor CG; Paya CV
    Clin Infect Dis; 1995 May; 20(5):1346-53. PubMed ID: 7620022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection.
    Winston DJ; Imagawa DK; Holt CD; Kaldas F; Shaked A; Busuttil RW
    Transplantation; 1995 Dec; 60(11):1357-60. PubMed ID: 8525537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.